QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

$137.32
-1.36 (-0.98%)
(As of 04:00 PM ET)
Today's Range
$136.29
$140.07
50-Day Range
$127.73
$147.20
52-Week Range
$89.00
$233.42
Volume
912,573 shs
Average Volume
1.78 million shs
Market Capitalization
$21.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$166.95

Illumina MarketRank™ Stock Analysis

Analyst Rating
Hold
2.32 Rating Score
Upside/​Downside
21.3% Upside
$166.95 Price Target
Short Interest
Healthy
3.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.61mentions of Illumina in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$991,676 Bought Last Quarter
Proj. Earnings Growth
162.64%
From $0.91 to $2.39 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.65 out of 5 stars

Medical Sector

70th out of 938 stocks

Analytical Instruments Industry

1st out of 28 stocks

ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Illumina (NASDAQ:ILMN) Given Mixed Rating at OTR Global
ILMN May 2024 120.000 put
ILMN Mar 2024 124.000 put
ILMN Mar 2024 155.000 call
ILMN Mar 2024 131.000 put
ILMN Mar 2024 115.000 put
ILMN Mar 2024 127.000 call
Carl Icahn Drops Plans for New Proxy Fight at Illumina
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/28/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,300
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$166.95
High Stock Price Target
$258.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+20.4%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
19 Analysts

Profitability

Net Income
$-1,161,000,000.00
Pretax Margin
-24.80%

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$3.71 per share
Book Value
$36.18 per share

Miscellaneous

Free Float
158,693,000
Market Cap
$22.04 billion
Optionable
Optionable
Beta
1.19

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Joydeep Goswami M.B.A. (Age 53)
    Ph.D., CFO, Chief Strategy & Corporate Development Officer
    Comp: $787.3k
  • Mr. Jacob Thaysen Ph.D. (Age 49)
    CEO & Director
  • Stephanie Campos
    President
  • Mr. Kevin Carl Pegels (Age 57)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 52)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Carissa L. Rollins (Age 53)
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations
  • Mr. Charles E. Dadswell Esq. (Age 65)
    Senior VP & General Counsel
    Comp: $1.06M
  • Ms. Kathryne Gambrell Reeves (Age 55)
    Chief Marketing Officer

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Illumina was last updated on Monday, March 25, 2024 at 11:12 PM.

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina offers sequencing and array-based solutions for genetic and genomic analysis, catering to a wide range of customers including research centers, academic institutions, and commercial laboratories.
  • The company is developing innovative solutions to accelerate cancer diagnoses, detect minimal residual disease, and enhance post-diagnostic applications, showing a commitment to advancing healthcare.
  • Illumina's multi-cancer early detection test, Galleri, provides a promising avenue for early cancer detection, potentially revolutionizing cancer screening methods.
  • The company's focus on genomics and genetic analysis places it at the forefront of cutting-edge technology in the life sciences industry, offering investors exposure to a rapidly evolving sector.
  • Recent positive market ratings and institutional investor holdings indicate confidence in Illumina's growth potential, which can be appealing to investors seeking long-term opportunities.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Market volatility and fluctuations in the life sciences industry can impact Illumina's stock price, potentially leading to short-term uncertainties for investors.
  • Regulatory challenges and changes in healthcare policies may affect the demand for Illumina's products and services, introducing risks related to evolving industry regulations.
  • Competition from other companies in the genomics and genetic analysis space could pressure Illumina's market share and margins, posing challenges to sustained growth and profitability.
  • Investing in analytical instrument companies like Illumina requires understanding complex technologies and industry-specific terms, which may pose a learning curve for some investors unfamiliar with the sector.
  • Fluctuations in research funding, particularly in government institutions and academic centers, can impact Illumina's revenue streams, highlighting the sensitivity of the company's financial performance to external factors.

ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price target for 2024?

19 analysts have issued 1-year price targets for Illumina's stock. Their ILMN share price targets range from $80.00 to $258.00. On average, they predict the company's stock price to reach $166.95 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 at the beginning of the year. Since then, ILMN stock has decreased by 1.2% and is now trading at $137.60.
View the best growth stocks for 2024 here
.

Are investors shorting Illumina?

Illumina saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 5,210,000 shares, an increase of 5.3% from the February 29th total of 4,950,000 shares. Based on an average daily volume of 1,780,000 shares, the short-interest ratio is presently 2.9 days.
View Illumina's Short Interest
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Thursday, February, 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The life sciences company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive trailing twelve-month return on equity of 2.20% and a negative net margin of 25.78%. Illumina's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.14 earnings per share.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.45%), Vanguard Group Inc. (11.44%), Edgewood Management LLC (4.33%), Baillie Gifford & Co. (3.32%), Wellington Management Group LLP (2.04%) and GUARDCAP ASSET MANAGEMENT Ltd (1.29%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
This page (NASDAQ:ILMN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners